Hemogenyx Pharmaceuticals (LON:HEMO) Hits New 52-Week Low – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares hit a new 52-week low on Tuesday . The stock traded as low as GBX 0.87 ($0.01) and last traded at GBX 0.98 ($0.01), with a volume of 16328066 shares. The stock had previously closed at GBX 0.93 ($0.01).

Hemogenyx Pharmaceuticals Stock Up 6.5 %

The stock has a fifty day moving average of GBX 1.34 and a two-hundred day moving average of GBX 1.36. The company has a quick ratio of 6.72, a current ratio of 4.38 and a debt-to-equity ratio of 92.09. The stock has a market cap of £15.28 million, a price-to-earnings ratio of -114.00 and a beta of 3.14.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.